Daniel Lapinski Appointed Member of Plaintiffs’ Steering Committee In Proton-Pump Inhibitor Products Liability Litigation


Wilentz, Goldman & Spitzer is pleased to announce that on August 23, 2017, Daniel Lapinski was appointed as a member of the Plaintiffs' Steering Committee in In re: Proton-Pump Inhibitor Products Liability Litigation, MDL No. 2789.

The coordinated litigation is currently centralized before the Honorable Claire C. Cecchi, United States District Judge, in the United States District Court for the District of New Jersey.  Proton-Pump Inhibitors (PPIs) are a class of medications commonly used to treat gastroesophageal reflux (GERD), dyspepsia , gastric ulcers and acid peptic disease. The more popular forms of PPIs include Prilosec, Prevacid, Nexium and AcipHex.  Complaints against the manufacturers of these popular medications allege that the drugs are linked to an increased risk of chronic kidney disease and acute kidney injury.

If you or someone you know has experienced problems after having used proton-pump inhibitors, contact Mr. Lapinski.